Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONCOGREEN study
2025-521273-14-00Phase 2Authorised
- Sponsor
- University of Milan
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of indocyanine green in gastrointestinal neoplasia, colorectal cancer (CRC), gastric cancer (GC) and 4 more, sponsored by University of Milan. Primary endpoints: Overall safety profile and dose-limiting toxicities (Phase I) and Diagnostic accuracy of OncoGreen intraoperative imaging (Phase II). Planned start Jun 2025; status: authorised.
02
Drugs
indocyanine green
03
Conditions
gastrointestinal neoplasiacolorectal cancer (CRC)gastric cancer (GC)liver cancerbiliary cancer
Beyond the preview
Go deeper on 2025-521273-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521273-14-00.